Ladenburg analyst Aydin Huseynov raised the firm’s price target on Aileron Therapeutics to $19 from $9 and keeps a Buy rating on the shares ahead of the company’s expected report of biomarker data for LTI-03 on 24 patients in Q3. The breadth of the biomarkers tested is “rather unprecedented” for any idiopathic pulmonary fibrosis, or IPF, trials, says the analyst, who raised the firm’s view of the odds of success to 40% from 20%, citing recent developments and the commitment by Aileron to guide its next trials by the biomarker readouts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALRN:
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Aileron Therapeutics Announces CFO Transition and Appointment
- Aileron Therapeutics Announces CEO Transition and Board Update
- Aileron Therapeutics CEO Manuel Aivado steps down, Brian Windsor to succeed
- Aileron Therapeutics: Board Shake-Up and Nasdaq Compliance Success
